U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Preparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Preparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs Guidance for Industry and FDA Staff April 2008

Download the Final Guidance Document
Final
Docket Number:
FDA-2020-D-0957
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

This document was developed to describe our recommendations for IDE applications for total artificial disc devices. It provides guidance for developers on the appropriate pre-clinical tests and clinical trial designs to adequately evaluate the safety of these devices as well as their effectiveness to relieve symptoms of spinal etiology and improve quality of life. This document makes additional recommendations and supplements “Guidance Document for the Preparation of IDEs for Spinal Systems” (i.e., Spinal Systems Guidance).

The purpose of this document is to provide guidance to industry sponsors and FDA staff about important preclinical and clinical information, which should be presented in an Investigational Device Exemption (IDE) application for total intervertebral disc replacement systems (i.e., total artificial discs). FDA is issuing this document to help ensure consistency and understanding between FDA and sponsors when developing IDE submissions for total artificial discs. We hope this guidance will conserve FDA and industry resources and facilitate timely review.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-0957.

Back to Top